Madrigal logo.jpg
Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights
May 06, 2021 06:50 ET | Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first quarter 2021 financial results and highlights. “We expect several...
Christopher Graybill Joins ARCA as Vice President, Clinical Development
May 05, 2021 16:05 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Clinical Highlights: 2021 CMHC Spring Cardiometabolic Health Congress
April 22, 2021 16:32 ET | Cardiometabolic Health Congress
Boca Raton, FL, April 22, 2021 (GLOBE NEWSWIRE) -- Clinical Highlights: 2021 CMHC Spring Cardiometabolic Health Congress Top Experts Convene to Discuss the Syndemic of COVID-19 &...
TIP_link_300x300.jpg
Microcatheters Market Revenue to Cross USD 773 Million by 2027: The Insight Partners Global Analysis with COVID-19 Impact
April 08, 2021 10:30 ET | The Insight Partners
Pune, India, April 08, 2021 (GLOBE NEWSWIRE) -- According to our new research study on “Microcatheters Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Indication and End...
Madrigal logo.jpg
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
February 25, 2021 06:50 ET | Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We...
Casana Raises $14 Million in Series A Funding Led by General Catalyst for In-home Heart Health Monitoring Device
February 03, 2021 08:12 ET | Casana Care, Inc.
ROCHESTER, N.Y., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Casana, previously known as Heart Health Intelligence, Inc., a healthcare technology firm that is re-inventing in-home health monitoring, today...
Reports and Data.jpeg-01
Biomarkers Market Size Worth $115.45 Billion By 2027 | CAGR of 13.6%: Reports And Data
December 11, 2020 11:21 ET | Reports and Data
New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- The market growth is driven by technological advancements in post-genomic technologies and extensive applications of diagnostic biomarkers in precision...
22157.jpg
Global Atrial Fibrillation Treatment Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast
December 10, 2020 04:13 ET | Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
Madrigal logo.jpg
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
November 13, 2020 06:50 ET | Madrigal Pharmaceuticals, Inc.
Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday,...
Madrigal logo.jpg
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
November 05, 2020 06:50 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in...